Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Insulin Glargine in DKA
NCT06007508Phase 2Terminated
- Sponsor
- HealthPartners Institute
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of insulin glargine in diabetic ketoacidosis (DKA) (2 arms), sponsored by HealthPartners Institute. Primary endpoint: ICU Length of Stay up to 12 weeks. Started May 2022; status: terminated.
02
Drugs
insulin glargine
03
Conditions
diabetic ketoacidosis (DKA)
Beyond the preview
Go deeper on NCT06007508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007508.